Immunotherapy for breast cancer

past, present, and future

Alison Spellman, Shou-Ching Tang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.

Original languageEnglish (US)
Pages (from-to)525-546
Number of pages22
JournalCancer and Metastasis Reviews
Volume35
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Immunotherapy
Breast Neoplasms
Therapeutics
Bispecific Antibodies
Tumor Microenvironment
Non-Small Cell Lung Carcinoma
Patient Selection
Melanoma
Vaccination
Biomarkers
Monoclonal Antibodies
Clinical Trials
Drug Therapy
Antibodies
Pharmaceutical Preparations
Neoplasms

Keywords

  • Biomarkers
  • Breast cancer
  • Checkpoint inhibitor
  • Clinical trials
  • Immunotherapy
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy for breast cancer : past, present, and future. / Spellman, Alison; Tang, Shou-Ching.

In: Cancer and Metastasis Reviews, Vol. 35, No. 4, 01.12.2016, p. 525-546.

Research output: Contribution to journalArticle

Spellman, Alison ; Tang, Shou-Ching. / Immunotherapy for breast cancer : past, present, and future. In: Cancer and Metastasis Reviews. 2016 ; Vol. 35, No. 4. pp. 525-546.
@article{14161f8ccf3b4ee2930a1cbc5926b540,
title = "Immunotherapy for breast cancer: past, present, and future",
abstract = "Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.",
keywords = "Biomarkers, Breast cancer, Checkpoint inhibitor, Clinical trials, Immunotherapy, Review",
author = "Alison Spellman and Shou-Ching Tang",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10555-016-9654-9",
language = "English (US)",
volume = "35",
pages = "525--546",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Immunotherapy for breast cancer

T2 - past, present, and future

AU - Spellman, Alison

AU - Tang, Shou-Ching

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.

AB - Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.

KW - Biomarkers

KW - Breast cancer

KW - Checkpoint inhibitor

KW - Clinical trials

KW - Immunotherapy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85000962117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000962117&partnerID=8YFLogxK

U2 - 10.1007/s10555-016-9654-9

DO - 10.1007/s10555-016-9654-9

M3 - Article

VL - 35

SP - 525

EP - 546

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 4

ER -